The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Treatment considerations for IgHV-unmutated and mutated CLL
In this video, Francesco Forconi, MD, DM, PhD, FRCPath, University of Southampton, Southampton, UK, discusses genetic drivers in chronic lymphocytic leukemia (CLL), drawing focus on somatic hypermutations of the IgHV genes, and how to approach treatment in these patients. First, Dr Forconi explains the process of the development of this mutation in CLL, and further discusses the poorer outcome and shorter progression-free survival (PFS) associated with IgHV-unmutated patients compared to IgHV-mutated patients. Dr Forconi then goes on to discuss the important role that Bruton’s tyrosine kinase (BTK) and BCL2 inhibitors have played in improving outcomes for IgHV-unmutated patients, as well as the importance of using data from clinical trials to guide treatment combinations in the future. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
